FDA Revokes Approval for Cancer Drug TAZVERIK

The Food and Drug Administration has withdrawn its approval for the cancer medication TAZVERIK, effective today. This action follows a voluntary request from the manufacturer, Epizyme, Inc., due to safety concerns. A confirmatory clinical trial revealed an increased rate of second primary malignancies, leading to the decision for the drug, which was initially approved under an accelerated pathway.